GIST Wishes!
Here are some #GISTWishes from our LRG Community shared in our December 2021 newsletter.
Here are some #GISTWishes from our LRG Community shared in our December 2021 newsletter.
The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.
A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent [...]
Pfizer Pharmaceuticals is offering Sutent in Touch, a program to support GIST patients on its drug Sutent. The program is free and patients can sign up by calling (1-877-578-8368). Sutent in Touch links patients to Oncology [...]
The first in a series of New York Times articles by science writer Gina Kolata on new approaches to cancer treatment underscored the type of cutting-edge approaches taken by the Life Raft Group’s own team of researchers. [...]
Social Media, such as Twitter, Facebook and LinkedIn, are an integral part of the daily lives of millions of people all over the world. People of all ages and backgrounds use social media, and now [...]
An agreement to secure the entry of Gleevec for Guatemalan GIST and chronic myeloid leukemia patients was reached with the Central American country’s government July 10, following advocacy efforts by Novartis Pharmaceuticals, Alianza GIST and [...]
Alianza GIST and Oncoguia have formalized a new partnership to work together to benefit GIST patients in Brazil. The first goal of this partnership is to identify GIST patients in the different regions of [...]
A new gene panel takes mutation testing to a new level. The panel tests for mutations in 23 genes at once will help to properly classify wild-type GIST patients. Working with next generation sequencing [...]
By Jim Hughes Here are updates from the American Society of Clinical Oncology conference on three GIST clinical trials. Panobinostat (HDAC) Phase 1 in 3rd Line GIST: LRG research Team member Sebastian Bauer, MD of Essen University [...]